Author's Accepted Manuscript

Differences in the Treatment of Benign Prostatic Hyperplasia: Comparing the Primary Care Physician and the Urologist

Adam J. Rensing, MD, Adrienne Kuxhausen, MS, Joel Vetter, MS, Seth A. Strope, MD, MPH



PII: S2352-0779(16)30196-0 DOI: 10.1016/j.urpr.2016.07.002

Reference: URPR 214

To appear in: *Urology Practice* Accepted Date: 14 July 2016

Please cite this article as: Rensing AJ, Kuxhausen A, Vetter J, Strope SA, Differences in the Treatment of Benign Prostatic Hyperplasia: Comparing the Primary Care Physician and the Urologist, *Urology Practice* (2016), doi: 10.1016/j.urpr.2016.07.002.

DISCLAIMER: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our subscribers we are providing this early version of the article. The paper will be copy edited and typeset, and proof will be reviewed before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to The Journal pertain.

All press releases and the articles they feature are under strict embargo until uncorrected proof of the article becomes available online. We will provide journalists and editors with full-text copies of the articles in question prior to the embargo date so that stories can be adequately researched and written. The standard embargo time is 12:01 AM ET on that date.

ACCEPTED MANUSCRIPT

Differences in the Treatment of Benign Prostatic Hyperplasia: Comparing the Primary Care Physician and the Urologist

Adam J. Rensing, MD, Adrienne Kuxhausen, MS, Joel Vetter, MS, Seth A. Strope, MD, MPH

Washington University School of Medicine, Division of Urologic Surgery

Abstract word count: 250

Word count: 2376

Conflicts of Interest: Nothing to Disclose

Source of Funding: NIDDK Diseases Clinical Investigator Award (1K08DK097302-01A1)UL1 TR000448 from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH), Grant Number R24 HS19455 through the Agency for Healthcare Research and Quality (AHRQ), and Grant Number KM1CA156708 through the National Cancer Institute (NCI) at the National Institutes of Health (NIH).

Corresponding Author:

Seth A. Strope, M.D.
Division of Urology
Washington University School of Medicine
4960 Children's Place
St. Louis, MO 63110
stropes@wudosis.wustl.edu

Key words: benign prostatic hyperplasia, alpha blocker, primary care

Download English Version:

https://daneshyari.com/en/article/8830286

Download Persian Version:

https://daneshyari.com/article/8830286

<u>Daneshyari.com</u>